1 Day
المصدر:
The Fiscal Times
The Fiscal Times
جاهز للتشغيل
جاهز للتشغيل
Starting Wednesday, certain Medicare beneficiaries can access FDA-approved GLP-1 weight loss medications for $50 a month through a new trial called Medicare GLP-1 Bridge, which runs until the end of 2027. The program aims to reduce barriers caused by high medication costs and is limited to those with specific BMI and health conditions, excluding individuals already covered for related diseases. The initiative is temporary, with future coverage uncertain unless Congress passes legislation or CMS implements further pilot programs, as the government seeks data on the program’s effectiveness.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading